Potter, C. W. A history of influenza. J. Appl. Microbiol. 91, 572–579 (2001).

Article  CAS  PubMed  Google Scholar 

Creighton, C. A History of Epidemics in Britain from A.D. 664 to the Extinction of Plague (Cambridge Univ. Press, 1891).

Dowdle, W. R. Influenza A virus recycling revisited. Bull. World Health Organ. 77, 820–828 (1999).

CAS  PubMed  PubMed Central  Google Scholar 

Taubenberger, J. K., Reid, A. H., Krafft, A. E., Bijwaard, K. E. & Fanning, T. G. Initial genetic characterization of the 1918 “Spanish” influenza virus. Science 275, 1793–1796 (1997).

Article  CAS  PubMed  Google Scholar 

Iuliano, A. D. et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet 391, 1285–1300 (2018).

Article  PubMed  Google Scholar 

World Health Organization. Recommended composition of influenza virus vaccines for use in the 2021–2022 northern hemisphere influenza season. Wkly. Epidemiological Rec. 96, 77–88 (2021).

Google Scholar 

World Health Organization. Recommended composition of influenza virus vaccines for use in the 2022–2023 northern hemisphere influenza season. Wkly Epidemiological Rec. 97, 109–132 (2022).

Google Scholar 

Jackson, L. A. Using surveillance to evaluate influenza vaccine effectiveness. J. Infect. Dis. 199, 155–158 (2009).

Article  PubMed  Google Scholar 

Jackson, M. L. & Nelson, J. C. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 31, 2165–2168 (2013).

Article  PubMed  Google Scholar 

Sullivan, S. G., Tchetgen Tchetgen, E. J. & Cowling, B. J. Theoretical basis of the test-negative study design for assessment of influenza vaccine effectiveness. Am. J. Epidemiol. 184, 345–353 (2016).

Article  PubMed  PubMed Central  Google Scholar 

Feng, S., Cowling, B. J., Kelly, H. & Sullivan, S. G. Estimating influenza vaccine effectiveness with the test-negative design using alternative control groups: a systematic review and meta-analysis. Am. J. Epidemiol. 187, 389–397 (2018).

Article  PubMed  Google Scholar 

Li, L. et al. Heterogeneity in estimates of the impact of influenza on population mortality: a systematic review. Am. J. Epidemiol. 187, 378–388 (2018).

Article  PubMed  Google Scholar 

Kissling, E. et al. Influenza vaccine effectiveness against influenza A subtypes in Europe: results from the 2021-2022 I-MOVE primary care multicentre study. Influenza Other Respir. Viruses 17, e13069 (2022).

Article  PubMed  PubMed Central  Google Scholar 

McLean, H. Q. et al. Interim estimates of 2022-23 seasonal influenza vaccine effectiveness - Wisconsin, October 2022-February 2023. MMWR Morb. Mortal. Wkly Rep. 72, 201–205 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Skowronski, D. M. et al. Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23. Eur. Surveill. 28, 2300043 (2023).

Article  CAS  Google Scholar 

CDC. Manual for the Surveillance of Vaccine-preventable Disease. Chapter 6, Influenza. https://www.cdc.gov/vaccines/pubs/surv-manual/chpt06-influenza.html (2023).

Pulendran, B., Arunachalam, P. S. & O’Hagan, D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454–475 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coffman, R. L., Sher, A. & Seder, R. A. Vaccine adjuvants: putting innate immunity to work. Immunity 33, 492–503 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Geckin, B., Fohse, F. K., Dominguez-Andres, J. & Netea, M. G. Trained immunity: implications for vaccination. Curr. Opin. Immunol. 77, 102190 (2022).

Article  CAS  PubMed  Google Scholar 

Parker, L. et al. Effects of egg-adaptation on receptor-binding and antigenic properties of recent influenza A (H3N2) vaccine viruses. J. Gen. Virol. 97, 1333–1344 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850–856 (2011). Description of an antibody that bound to a conserved epitope in the fusion subdomain of haemagglutinin and offered protection in mice against influenza A (H1N1) and influenza A (H3N2) viruses and in ferrets against influenza A (H5N1) virus.

Article  CAS  PubMed  Google Scholar 

Ekiert, D. C. et al. Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246–251 (2009).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ekiert, D. C. et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333, 843–850 (2011).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kallewaard, N. L. et al. Structure and function analysis of an antibody recognizing all influenza A subtypes. Cell 166, 596–608 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xiao, H. et al. Light chain modulates heavy chain conformation to change protection profile of monoclonal antibodies against influenza A viruses. Cell Discov. 5, 21 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Krammer, F., Li, L. & Wilson, P. C. Emerging from the shadow of hemagglutinin: neuraminidase is an important target for influenza vaccination. Cell Host Microbe 26, 712–713 (2019).

Article  CAS  PubMed  Google Scholar 

Doyle, T. M. et al. Universal anti-neuraminidase antibody inhibiting all influenza A subtypes. Antivir. Res. 100, 567–574 (2013).

Article  CAS  PubMed  Google Scholar 

Rijal, P. et al. Broadly inhibiting antineuraminidase monoclonal antibodies induced by trivalent influenza vaccine and H7N9 infection in humans. J. Virol. 94, e01182-19 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Moore, K. A. et al. A research and development (R&D) roadmap for influenza vaccines: looking toward the future. Vaccine 39, 6573–6584 (2021). This describes a pathway to improved and universal influenza vaccines with links to an up-to-date tracking of their research and development.

Article  PubMed  Google Scholar 

Nachbagauer, R. et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat. Med. 27, 106–114 (2021).

Article  CAS  PubMed  Google Scholar 

Folschweiller, N. et al. Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial. Lancet Infect. Dis. 22, 1062–1075 (2022).

Article  CAS  PubMed  Google Scholar 

Lewis, N. M. et al. Interpretation of relative efficacy and effectiveness for influenza vaccines. Clin. Infect. Dis. 75, 170–175 (2022).

Article  PubMed  Google Scholar 

Izurieta, H. S. et al. Relative effectiveness of cell-cultured and egg-based influenza vaccines among elderly persons in the United States, 2017-2018. J. Infect. Dis. 220, 1255–1264 (2019).

Article  CAS  PubMed  Google Scholar 

Izurieta, H. S. et al. Relative effectiveness of influenza vaccines among the United States elderly, 2018-2019. J. Infect. Dis. 222, 278–287 (2020).

Article  CAS  PubMed  Google Scholar 

Izurieta, H. S. et al. Comparative effectiveness of influenza vaccines among US medicare beneficiaries ages 65 years and older during the 2019-2020 season. Clin. Infect. Dis. 73, e4251–e4259 (2021). The third of a series of reports on the relative vaccine effectiveness of enhanced seasonal influenza vaccines compared with standard egg-based vaccines in preventing hospital encounters among people aged >65 during the last influenza season prior to the emergence of COVID-19.

Article  CAS  PubMed  Google Scholar 

Boikos, C. et al. Relative effectiveness of adjuvanted trivalent inactivated influenza vaccine versus egg-derived quadrivalent inactivated influenza vaccines and high-dose trivalent influenza vaccine in preventing influenza-related medical encounters in US adults ≥65 years during the 2017-2018 and 2018-2019 influenza seasons. Clin. Infect. Dis. 73, 816–823 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Boikos, C. et al. Relative effectiveness of the cell-derived inactivated quadrivalent influenza vaccine versus egg-derived inactivated quadrivalent influenza vaccines in preventing influenza-related medical encounters during the 2018-2019 influenza season in the United States. Clin. Infect. Dis. 73, e692–e698 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Whitney, C. G. et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348, 1737–1746 (2003).

Article  PubMed  Google Scholar 

Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).

Article  CAS  PubMed  Google Scholar 

Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).

Article